Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

301.35USD
22 May 2015
Change (% chg)

$0.13 (+0.04%)
Prev Close
$301.22
Open
$300.59
Day's High
$303.66
Day's Low
$300.31
Volume
373,800
Avg. Vol
633,418
52-wk High
$317.72
52-wk Low
$202.00

ACT.N

Chart for ACT.N

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $118,361.00
Shares Outstanding(Mil.): 392.77
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): -- 37.22 39.17
EPS (TTM): -8.49 -- --
ROI: -2.96 16.24 15.58
ROE: -5.95 16.99 16.57
Search Stocks

UPDATE 2-Actavis cannot drop old version of Alzheimer's drug -appeals court

NEW YORK, May 22 - Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court in New York ruled on Friday.

23 May 2015

Actavis cannot drop old version of Alzheimer's drug - appeals court

NEW YORK, May 22 - Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court ruled on Friday.

22 May 2015

Actavis says Warner Chilcott unit held talks to settle U.S. probe

- Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales activities, according to a regulatory filing.

15 May 2015

Actavis says Warner Chilcott unit held talks to settle U.S. probe

May 14 - Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales activities, according to a regulatory filing.

15 May 2015

UPDATE 2-Actavis expects Allergan business to drive 2015 growth

* Expects 2015 rev of $20.5-$21 bln; adj rev of $22-$22.5 bln

11 May 2015

BRIEF-Molecular Partners: Actavis confirms timeline for start of phase III development of Abicipar

* Actavis confirms timeline for start of phase III development of Abicipar

11 May 2015

Actavis revenue jumps 60 pct

May 11 - Drugmaker Actavis Plc's quarterly revenue jumped almost 60 percent, helped by higher sales of its branded drugs in North America, but charges related to its acquisition of Botox maker Allergan Inc pushed the company into a net loss.

11 May 2015

U.S. court weighs whether to let Actavis drop Alzheimer's drug

NEW YORK, April 13 - Actavis Plc urged a U.S. appeals court on Monday to allow it to discontinue a top-selling Alzheimer's drug in favor of a pricier extended-release version, a move that New York's attorney general has said would suppress generic competition.

14 Apr 2015

EU mergers and takeovers (March 17)

BRUSSELS, March 17 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

17 Mar 2015

BRIEF-American Airlines to join S&P 500

March 16 - * S&P Dow jones indices says American Airlines Group Inc to replace

17 Mar 2015

Earnings vs. Estimates

Search Stocks